GenesisTissue

What GenesisTissue does

GenesisTissue Inc. is a Denver, Colorado-based tissue engineering company founded in 2024 that develops personalized, bioresorbable scaffolds produced via precision 3D bioprinting. The company's lead product, the RBT Scaffold (Rapid Bioresorbable Tissue Scaffold), is a degradable, patient-specific breast tissue scaffold intended to support reconstructive and regenerative applications for women undergoing breast-related procedures. The platform combines proprietary biomaterials with additive manufacturing, enabling each scaffold to be designed to the patient's anatomy rather than produced as a one-size-fits-all implant.

The technical foundation rests on three reported capabilities: Precision 3D Bioprinting, Biomaterial Innovation, and Personalized Design. The founding CEO, Katie Weimer (MS, MBA), brings prior experience in 3D printing for healthcare, with 15+ peer-reviewed publications, two associated patents, and a career track record that includes work on 100+ FDA-cleared and CE-marked devices — credentials that materially de-risk the regulatory translation path relative to typical early-stage tissue engineering teams. GenesisTissue has also built a regional support network through a Colorado State University partnership, Innosphere incubator affiliation, and a $250,000 non-dilutive grant from the Colorado Office of Economic Development and International Trade (OEDIT) in 2025. In 2026, the company was accepted into the MedTech Innovator cohort (top 4% of applicants), expanding its visibility to national investors and clinical partners.

Commercial revenue mechanics are not yet established. As a regulated medical device with no disclosed FDA filing to date, the RBT Scaffold is pre-commercial; revenue is expected to depend on eventual regulatory clearance followed by direct-to-hospital and surgeon-channel sales or licensing arrangements typical of reconstructive implants. Customer logos, pricing, and go-to-market plans are not disclosed in the available input, consistent with the company's pre-revenue stage.

Name

GenesisTissue

Legal name

GenesisTissue Inc.

Website

https://genesistissue.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

GenesisTissue Inc. is a Denver-based, 2024-founded tissue engineering company that develops personalized, bioresorbable 3D-bioprinted breast tissue scaffolds (RBT Scaffold) for reconstructive and regenerative surgical applications, serving hospitals and reconstructive surgeons.

Ownership category

akta.pro rank

Product category

Regenerative Medical Devices (Tissue Engineering)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

akta.pro secondary industries

3D Bioprinting & Biofabrication (HLAAAGAC), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)

Keywords

• 3D bioprinting tissue
• Regenerative tissue implants
• Breast tissue scaffolds
• Bioprinted medical devices
• Personalized regenerative medicine

Headquarters

HQ city

Denver

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Regenerative Tissue Implants: Sale of personalized 3D bioprinted tissue scaffolds for breast reconstruction and lumpectomy procedures. The company manufactures proprietary regenerative implants that replace legacy industrial materials with living, regenerative solutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

GenesisTissue Inc. is a 3D bioprinting tissue company that designs and manufactures personalized regenerative tissue implants for humans using a proprietary platform combining precision 3D bioprinting, biomaterial innovation, and personalized design. The company's lead product is the RBT (Rapid Bioresorbable Tissue) Scaffold — a degradable, bioprinted breast tissue scaffold personalized for each patient that is designed to become 100% native tissue in the breast. Target use cases include breast reconstruction after mastectomy, breast-conserving lumpectomy procedures, augmentation revision, and implant removal procedures.

Product overview

GenesisTissue is a 3D bioprinting tissue company offering personalized regenerative tissue implants. The company's core product is the RBT Scaffold, a degradable bioprinted breast tissue scaffold personalized for each patient that is designed to become 100% native tissue. This product is supported by three integrated technology pillars: Precision 3D Bioprinting (for fabrication), Biomaterial Innovation (for degradable scaffold materials), and Personalized Design (for patient-specific customization). The company was founded in 2024.

Differentiator

Problem solved

Functional benefit

Products and services

• RBT Scaffold (Rapid Bioresorbable Tissue Scaffold) A degradable, 3D bioprinted breast tissue scaffold personalized for each patient and designed to become 100% native tissue in the breast. It is intended for breast reconstruction after mastectomy, breast-conserving lumpectomy procedures, augmentation revision, and implant removal procedures.

Quantifiable outcome

• 60% of women who undergo breast-conserving procedures need reoperations after initial lumpectomy surgery due to positive cancer margins
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• MedTech InnovatorcoreGTM or Marketing Partner · 1 January 2026GenesisTissue was selected as part of the top 4% of companies to join the prestigious MedTech Innovator 2026 cohort. This accelerator program provides mentorship, networking, and visibility within the medtech industry.
• Colorado State University (CSU)minorStrategic or Co-development PartnerListed as an ecosystem partner. University partnership likely focused on research collaboration and development of regenerative tissue technologies.
• InnosphereminorStrategic or Co-development PartnerListed as an ecosystem partner. Innosphere is a startup incubator/accelerator supporting technology companies in Colorado.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Stratasys: Stratasys is a major 3D printing systems and services company with established healthcare offerings including anatomical models, surgical guides, and patient-specific devices. It is a broad incumbent in medical 3D printing with significantly greater scale than GenesisTissue.
• BICO (formerly Cellink): BICO owns Cellink and other bioprinting and lab automation brands, providing bioprinters, bioinks, and regenerative medicine workflow tools. It is a broad incumbent in the bioprinting space, supplying the hardware and consumables that smaller companies like GenesisTissue use as inputs.
• 3D Systems: 3D Systems is a leading additive manufacturing company with a significant healthcare practice including patient-specific surgical planning, implants, and regenerative solutions. It is a broad incumbent comparable to GenesisTissue in the patient-specific medical 3D printing space, but with much broader scope and scale.
• Materialise: Materialise provides 3D printing software and services for medical applications including patient-specific implants, surgical guides, and personalized medical devices. It is a broad incumbent offering patient-specific medical 3D printing services comparable to GenesisTissue's personalized implant approach.

Emerging players

• Precise Bio: Precise Bio is an early-stage regenerative medicine company using 3D bio-fabrication to develop transplantable organs and tissues. It is an emerging peer to GenesisTissue using 4D-bioprinting technology for ophthalmology and other tissue applications, with overlapping bioprinting technology.
• Humabiologics: Humabiologics provides human-derived biomaterials and tissue engineering products for regenerative medicine research and clinical applications. It is an emerging peer comparable to GenesisTissue in the biomaterial innovation layer of tissue engineering.

Direct peers

• TeVido BioDevices: TeVido BioDevices develops 3D-bioprinted personalized tissue constructs, with a historical focus on breast reconstruction and nipple reconstruction using patient-derived cells. It is the closest direct competitor to GenesisTissue's RBT Scaffold product, addressing the same clinical use case with similar bioprinting technology.
• Organovo Holdings: Organovo is a pioneer in 3D bioprinting human tissues for therapeutic and research applications. It is a direct peer to GenesisTissue in bioprinted regenerative tissue, though historically focused on liver tissue and drug testing.
• CollPlant Biotechnologies: CollPlant develops regenerative tissue products and bioinks from plant-derived recombinant human collagen, used in 3D bioprinting of tissues and organs. It is directly comparable to GenesisTissue in the regenerative tissue and biomaterial innovation space, with a broader pipeline but similar core technology thesis.
• Aspect Biosystems: Aspect Biosystems is a bioprinting platform company developing living tissue therapeutics using microfluidic 3D bioprinting. It is comparable to GenesisTissue as a direct peer in personalized bioprinted tissue therapeutics with a similar business model and technology approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genesistissue

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenesisTissue